Can I Take Resveratrol with GHK-Cu?

What GHK-Cu and Resveratrol Actually Do

GHK-Cu (glycyl-L-histidyl-L-lysine copper complex) is a naturally occurring tripeptide first isolated from human plasma by Loren Pickart in 1973. Resveratrol is a polyphenolic stilbene found in grape skins, red wine, and Japanese knotweed. Both compounds attract interest for anti-aging and tissue-repair applications, which is why people stack them. But "longevity" is not a pharmacological class, and the two molecules work through distinct biology.

GHK-Cu: Mechanism and Pharmacology

GHK-Cu binds copper(II) with high affinity (log stability constant ~16.44) and delivers it to tissues where copper-dependent enzymes like lysyl oxidase and superoxide dismutase 1 (SOD1) require it [1]. In a 2018 gene-expression analysis, GHK-Cu modulated 4,049 human genes at a concentration of 1 micromolar, with upregulation of collagen-synthesis and DNA-repair pathways [2]. The peptide's half-life in human plasma is short, roughly 2 to 4 minutes, because aminopeptidases cleave it rapidly [3]. When administered subcutaneously, it reaches dermal and subdermal tissues before systemic degradation removes most of the intact molecule. Topical formulations (0.01% to 1% GHK-Cu) act locally and show negligible systemic absorption.

Resveratrol: Mechanism and Pharmacology

Resveratrol activates sirtuin-1 (SIRT1) and AMP-activated protein kinase (AMPK), two central regulators of cellular energy metabolism and stress response [4]. Oral bioavailability is low. A pharmacokinetic study in healthy volunteers given 25 mg oral resveratrol found peak plasma concentration of only 1 to 5 ng/mL, with rapid sulfation and glucuronidation producing metabolites that account for over 90% of circulating resveratrol-related species [5]. Resveratrol is metabolized primarily by CYP3A4, CYP1A2, and sulfotransferases. It also inhibits CYP3A4 and CYP1B1 in vitro at concentrations above 10 micromolar [6].

Is There a Known Drug Interaction?

No. As of May 2026, PubMed, the Natural Medicines Comprehensive Database, and the Mayo Clinic drug-interaction checker list zero entries for a direct GHK-Cu plus resveratrol interaction. That absence does not mean the combination is proven safe. It means no one has run a controlled study.

Why the Absence of Data Matters

GHK-Cu sits in a regulatory gray zone. The FDA has not approved it as a drug, and most clinical use occurs through 503A compounding pharmacies. Resveratrol is sold as a dietary supplement under DSHEA. Neither product triggers the mandatory interaction studies that FDA-approved drugs require before market entry. The result: clinicians must reason from first principles, using each compound's known pharmacology to estimate risk.

What Interaction Databases Show

The Natural Medicines database flags resveratrol for moderate interactions with CYP3A4 substrates and anticoagulants but does not list GHK-Cu at all [7]. The Endocrine Society's 2023 clinical practice guideline on hormone therapy does not address peptide-supplement stacking, though it does note that phytoestrogens (including resveratrol) may confound estrogen-sensitive lab assays [8].

Theoretical Interaction Pathways

Two mechanisms deserve attention: copper chelation (pharmacodynamic) and CYP3A4 inhibition (pharmacokinetic). A third, overlapping anti-inflammatory signaling, is unlikely to cause harm but could alter expected outcomes.

Copper Chelation by Resveratrol

Resveratrol contains two hydroxyl groups on its A-ring that can coordinate divalent metal ions, including copper(II). In vitro, resveratrol chelates Cu²⁺ with a binding constant in the micromolar range [9]. If oral resveratrol reaches the injection site or systemic circulation at sufficient concentration, it could theoretically strip copper from the GHK tripeptide backbone, converting active GHK-Cu into inactive apo-GHK.

The practical risk is low for two reasons. First, resveratrol's systemic bioavailability after oral dosing rarely exceeds 1 to 5 ng/mL (roughly 4 to 22 nanomolar), far below the micromolar concentrations needed for meaningful chelation [5]. Second, subcutaneous GHK-Cu acts locally before entering systemic circulation, so the two compounds occupy different compartments during peak activity.

"The chelation concern is a test-tube finding that does not automatically translate to in vivo relevance at supplemental doses," noted Dr. Richard Baxter, a Seattle-based plastic surgeon who has published on copper peptide wound healing [10].

CYP3A4 Inhibition

Resveratrol inhibits CYP3A4 with an IC₅₀ of approximately 2 to 12 micromolar in human liver microsomes [6]. If GHK-Cu were orally administered and hepatically metabolized, this would matter. But injectable GHK-Cu bypasses the liver entirely, and its degradation is peptidase-mediated, not CYP-mediated. For topical GHK-Cu, systemic CYP exposure is negligible.

The CYP3A4 concern becomes relevant only if you take other oral medications alongside resveratrol. Resveratrol at doses above 500 mg/day may increase plasma levels of CYP3A4 substrates like midazolam by 25 to 50% [11]. That interaction has nothing to do with GHK-Cu, but it is worth flagging if your supplement stack includes additional compounds metabolized by CYP3A4.

Overlapping Anti-Inflammatory Signaling

Both GHK-Cu and resveratrol suppress NF-κB-mediated inflammation. GHK-Cu downregulates IL-6 and TNF-alpha gene expression [2]. Resveratrol inhibits NF-κB through SIRT1-dependent deacetylation of the p65 subunit [4]. In theory, combining two NF-κB suppressors could produce additive anti-inflammatory effects. Whether that additive effect is beneficial (reduced chronic inflammation) or detrimental (impaired acute wound-healing response) depends on clinical context. Patients using GHK-Cu specifically for post-procedural wound repair may want to avoid high-dose resveratrol (above 500 mg/day) during the acute healing window.

Dose-Separation Protocol

Even without a documented interaction, separating the two compounds in time is a reasonable precaution that costs nothing.

Timing Recommendations

Take oral resveratrol with a meal (food improves absorption and reduces GI upset). Administer subcutaneous GHK-Cu at least two hours before or after the resveratrol dose. This window ensures that the brief spike in free resveratrol concentration has cleared the plasma compartment before GHK-Cu peptide fragments enter systemic circulation.

Dose Considerations

Most resveratrol supplements deliver 150 to 500 mg per day. GHK-Cu injection protocols typically range from 200 mcg to 1 mg subcutaneously, one to three times per week. At these standard doses, the chelation risk is negligible. If you take resveratrol above 1,000 mg/day (a dose some anti-aging protocols recommend), the interaction margin narrows, and closer monitoring of copper status becomes more appropriate.

Topical GHK-Cu and Oral Resveratrol

This is the lowest-risk combination. Topical GHK-Cu serums (typically 0.01% to 1%) act within the epidermis and dermis. Oral resveratrol metabolites circulate systemically. The two compartments barely overlap. No dose separation is needed.

Monitoring If You Take Both

Routine bloodwork is not mandatory for short-term combination use, but long-term users (beyond 12 weeks) should track copper homeostasis.

Recommended Labs

Check serum copper, ceruloplasmin, and zinc every three to six months. Copper and zinc compete for intestinal absorption via metallothionein, and supplemental copper from GHK-Cu could shift the Cu:Zn ratio over time [12]. Resveratrol's chelation activity, while weak in vivo, adds another variable. A healthy serum copper range is 70 to 150 mcg/dL. If levels drop below 70 mcg/dL or exceed 150 mcg/dL, pause GHK-Cu and reassess.

"We check copper and ceruloplasmin at baseline and at 90 days in any patient starting exogenous copper peptide therapy, regardless of what else they're taking," said Dr. Amy Killen, a regenerative medicine physician in Utah who prescribes GHK-Cu for skin and hair applications [13].

Signs of Copper Excess or Deficiency

Copper excess: nausea, metallic taste, liver enzyme elevation (AST/ALT above the upper limit). Copper deficiency: neutropenia, anemia, neuropathy. Both are rare at standard GHK-Cu doses but become more plausible with aggressive dosing or when multiple copper-modulating supplements are stacked.

When to Pause One or Both

Stop resveratrol if serum copper drops below 60 mcg/dL, as the chelation effect (however small) is working against your GHK-Cu goals. Stop GHK-Cu if serum copper exceeds 170 mcg/dL or if liver enzymes rise above 2x the upper reference limit. Resume only after labs normalize and your prescribing clinician has reviewed the results.

The Estrogenic Question

Resveratrol binds estrogen receptor beta (ERβ) with an IC₅₀ of approximately 50 micromolar, classifying it as a weak phytoestrogen [14]. At typical supplement doses (150 to 500 mg/day), circulating resveratrol concentrations stay well below 1 micromolar, making clinically meaningful estrogenic activity unlikely. A 2014 randomized trial of 1,000 mg/day trans-resveratrol in postmenopausal women (N=80) found no significant changes in serum estradiol, estrone, or sex hormone-binding globulin over 12 weeks compared to placebo [15].

When Estrogenic Activity Could Matter

Patients with estrogen receptor-positive breast cancer, endometriosis, or uterine fibroids should discuss resveratrol use with their oncologist or gynecologist regardless of GHK-Cu co-administration. The concern is resveratrol-specific, not combination-specific. GHK-Cu has no known estrogenic or anti-estrogenic activity.

What to Do If You Are Already Taking Both

If you have been combining oral resveratrol and injectable GHK-Cu without problems, there is no reason to stop abruptly.

Step 1: Establish a Baseline

Get a comprehensive metabolic panel (CMP) plus serum copper, ceruloplasmin, and zinc. If everything falls within normal range, continue with the dose-separation protocol described above.

Step 2: Space Your Doses

Shift to the two-hour separation window if you have not already. Many users take resveratrol with breakfast and inject GHK-Cu in the evening. That spacing provides more than adequate temporal separation.

Step 3: Reassess at 90 Days

Repeat labs at 90 days. If copper, zinc, liver enzymes, and CBC remain stable, the combination is likely well tolerated in your case. Continue with biannual monitoring.

Step 4: Watch for New Symptoms

Report any new onset of nausea, unusual fatigue, paresthesias in the hands or feet, or unexplained bruising to your clinician. These could signal copper dysregulation, resveratrol-anticoagulant interaction (if you take blood thinners), or an unrelated process.

What the Evidence Does Not Support

No published RCT has tested GHK-Cu plus resveratrol in humans for any endpoint. Marketing claims that the combination produces "synergistic anti-aging effects" or "amplified collagen synthesis" have no clinical trial backing. Individual components have mechanistic data; the pairing does not.

A 2020 in vitro study exposed human dermal fibroblasts to GHK-Cu (1 micromolar) plus resveratrol (10 micromolar) and reported a 34% increase in type I collagen expression compared to GHK-Cu alone, but the cell-culture model used concentrations far exceeding achievable plasma levels after oral resveratrol dosing [16]. Extrapolating from petri dish to patient is not valid without pharmacokinetic bridging data.

Patients should assess the combination as two parallel interventions rather than assuming pharmacological combination. If serum copper rises above 150 mcg/dL on repeat testing, reduce the GHK-Cu injection frequency from three times weekly to once weekly before adjusting resveratrol.